Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Mymetics Corp

Market Cap 439K 379K 349K 327K 613K 41.71M 622K 4.12M 1.61M 20.3M 1.65M 1.61M 70.29M P/E Ratio 2021
-1.86x
P/E Ratio 2022 -1.77x
Enterprise Value 72.12M 62.29M 57.4M 53.73M 101M 6.86B 102M 678M 264M 3.34B 271M 265M 11.55B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 2012-11-18
Change 5-day change 1-year change 3-year change Capi.($)
-11.43%+44.21% - - 45
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +0.48%+2.09%+27.72%+106.67% 23.75B
Weighted average by Cap. +1.72%+2.37%+32.04%+99.60%

Financials

2021 2022
Net sales 430K 371K 342K 320K 600K 40.87M 610K 4.04M 1.58M 19.89M 1.61M 1.58M 68.88M 1.03M 888K 818K 766K 1.44M 97.71M 1.46M 9.66M 3.77M 47.56M 3.86M 3.78M 165M
Net income -4.73M -4.09M -3.76M -3.52M -6.6M -450M -6.71M -44.45M -17.33M -219M -17.75M -17.37M -758M -4.8M -4.15M -3.82M -3.58M -6.71M -457M -6.81M -45.16M -17.61M -222M -18.03M -17.65M -770M
Net Debt 67.1M 57.95M 53.4M 49.99M 93.68M 6.38B 95.13M 631M 246M 3.1B 252M 246M 10.75B 71.68M 61.91M 57.05M 53.4M 100M 6.81B 102M 674M 263M 3.32B 269M 263M 11.48B
Logo Mymetics Corp
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!